Loading...
XOSLAZT
Market cap60mUSD
Dec 23, Last price  
13.40NOK
1D
-0.45%
1Q
-25.06%
Jan 2017
18.58%
IPO
-41.67%
Name

Arcticzymes Technologies ASA

Chart & Performance

D1W1MN
XOSL:AZT chart
P/E
35.23
P/S
5.75
EPS
0.38
Div Yield, %
0.00%
Shrs. gr., 5y
1.96%
Rev. gr., 5y
12.24%
Revenues
119m
-13.16%
147,202,27270,041,00072,973,00073,217,00051,702,00024,075,00025,909,00023,032,00021,475,00022,108,00033,026,00053,280,00071,904,00066,686,00066,769,00077,247,00093,449,000127,970,000136,971,000118,939,000
Net income
19m
-40.89%
-2,735,328-15,446,000-26,654,000-18,665,000-52,179,000-99,372,000-28,541,000-20,103,000-24,318,000-22,889,000-21,992,000-17,344,000-20,480,000-24,938,000-13,989,000-7,183,00083,119,00046,380,00032,860,00019,425,000
CFO
24m
-57.95%
-3,046,449-8,468,000-32,590,0000-65,657,000-89,000,000-24,965,000-10,811,000-24,583,000-17,385,000-21,200,000-12,886,000-19,278,000-22,056,000-18,279,0003,965,00046,928,00074,970,00058,094,00024,430,000
Earnings
Jan 30, 2025

Profile

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing. It offers salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining DNA /RNA fragments. It operates in Norway, Germany, Lithuania, Italy, other countries in Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was incorporated in 1990 and is headquartered in Tromsø, Norway.
URL
https://arcticzymes.com/
IPO date
Nov 04, 2005
Employees
60
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
118,939
-13.16%
136,971
7.03%
127,970
36.94%
Cost of revenue
28,504
30,053
26,216
Unusual Expense (Income)
NOPBT
90,435
106,918
101,754
NOPBT Margin
76.03%
78.06%
79.51%
Operating Taxes
5,340
9,283
12,621
Tax Rate
5.90%
8.68%
12.40%
NOPAT
85,095
97,635
89,133
Net income
19,425
-40.89%
32,860
-29.15%
46,380
-44.20%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,584
1,600
1,600
BB yield
-0.12%
-0.04%
-0.03%
Debt
Debt current
4,174
3,732
3,097
Long-term debt
21,002
24,428
32,041
Deferred revenue
Other long-term liabilities
1,000
2
(1,000)
Net debt
(153,439)
(213,870)
(163,639)
Cash flow
Cash from operating activities
24,430
58,094
74,970
CAPEX
(1,673)
(12,432)
(11,598)
Cash from investing activities
(21,015)
(12,432)
(11,564)
Cash from financing activities
(1,316)
(1,924)
(3,160)
FCF
75,785
103,132
84,001
Balance
Cash
249,862
242,030
198,777
Long term investments
(71,247)
Excess cash
172,668
235,181
192,378
Stockholders' equity
45,350
23,080
(15,412)
Invested Capital
276,536
275,738
277,824
ROIC
30.82%
35.28%
40.44%
ROCE
28.10%
35.78%
38.78%
EV
Common stock shares outstanding
50,841
50,928
50,553
Price
42.00
-41.38%
71.65
-23.78%
94.00
47.80%
Market cap
2,135,322
-41.48%
3,648,991
-23.21%
4,751,982
52.11%
EV
1,981,883
3,435,121
4,588,343
EBITDA
96,816
111,939
104,945
EV/EBITDA
20.47
30.69
43.72
Interest
498
499
694
Interest/NOPBT
0.55%
0.47%
0.68%